HealthTechAppointmentsInvestment

YFM Equity Partners has led an investment round into Psychology Tools, a specialist online platform designed to support mental health professionals with best practice evidence-based resources, tools, and guidance.  

The funding will enable Psychology Tools, which is headquartered in Reading, to invest in expanding its team and accelerate its growth plans. 

Chris Berry and Allan Oehlers – both formerly of CIPHR – have joined as chair and COO respectively as part of the investment deal.

The business is one of the world’s leading providers of online resources to psychologists, therapists, counsellors, and other mental health professionals. Users access its content, which includes downloadable worksheets, exercises, information handouts, guides, and audio therapy resources, via annual subscription to an online platform. 

Founded in 2008 by clinical psychologist Dr Matthew Whalley (pictured), Psychology Tools has since grown to be a highly regarded source of support to therapy professionals and their clients. As well as publishing resources for professionals, Psychology Tools is dedicated to supporting the public by providing free, high-quality mental health information.

Spinout develops treatment for diabetics at risk of amputation

“With the backing of YFM and our new team members in place, we look forward to supporting even more mental health professionals,” said Dr Whalley. 

“We are excited about creating an even broader range of resources, and developing more ways for clients to interact with them.”

Adam Hart, YFM investment director, added: “Psychology Tools is a great example of a business that has flourished as a result of a founder’s passion and dedication. It has an outstanding reputation for quality content and accessibility. 

“With YFM’s investment and the expert guidance of the new Chair and COO, we are confident that Psychology Tools can execute a growth plan that will benefit both the business and its thousands of users across the globe.”

MIP Discovery raises £7m to advance cell and gene therapies